Idiosyncratic drug-induced liver injury: an update on the 2007 overview (Q38145274)

29 August 2017

Idiosyncratic drug-induced liver injury: an update on the 2007 overview (English)

1 reference

29 August 2017

S Hyder Hussaini

1

1 reference

PubMed ID

24073714

29 August 2017

Elizabeth Anne Farrington

series ordinal

2

1 reference

PubMed ID

24073714

29 August 2017

language of work or name

English

0 references

publication date

27 September 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

1 reference

29 August 2017

13

1 reference

29 August 2017

1

1 reference

29 August 2017

67-81

1 reference

Drug-induced liver injury: summary of a single topic clinical research conference

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Epidemiology of idiosyncratic drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Liver transplantation for acute liver failure from drug induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Idiosyncratic drug-induced liver injury: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Incidence of drug-induced hepatic injuries: a French population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Acute liver failure due to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Case definition and phenotype standardization in drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Antibiotic therapy: a major cause of drug-induced jaundice in southwest England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Current concepts of mechanisms in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Diagnosis, management and prevention of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Pharmacogenetics of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Arylamine N-acetyltransferase-2 genotypes in the Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Idiosyncratic drug reactions: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

HLA association of amoxicillin-clavulanate--induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The bile salt export pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The role of hepatitis E virus testing in drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Idiosyncratic drug reactions: the reactive metabolite syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Mitochondria in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatitis E acquired in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatitis E in new zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Autochthonous hepatitis E in southwest England

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatitis E virus and chronic hepatitis in organ-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Immune-mediated drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The pathology of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Review article: drug-induced liver injury in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Early indicators of prognosis in fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The natural history of histologically proved drug induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug-induced hepatotoxicity: 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug metabolism and drug interactions in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Incidence of drug-induced liver injury in medical inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Acute and clinically relevant drug-induced liver injury: a population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Incidence of statin hepatotoxicity in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The myth of statin-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Acute cholestatic hepatitis associated with long-term use of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

COX-2 selective inhibitors in the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Serious liver disease induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Safety of green tea extracts : a systematic review by the US Pharmacopeia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Circulating microRNAs, potential biomarkers for drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

The potential of cytokines as safety biomarkers for drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.828032

10.1517/14740338.2013.828032

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24073714